ProShare Advisors
VRDN icon

ProShare Advisors’s Viridian Therapeutics VRDN Stock Holding History

ProShare Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$231K Sell
11,794
-2,809
-19% -$83.4K ﹤0.01% 1488
2025
Q4 		$454K Buy
14,603
+2,597
+22% +$71.2K ﹤0.01% 1182
2025
Q3 		$259K Sell
12,006
-2,239
-16% -$40.4K ﹤0.01% 1534
2025
Q2 		$199K Sell
14,245
-1,907
-12% -$25.9K ﹤0.01% 1724
2025
Q1 		$218K Sell
16,152
-4,432
-22% -$75.5K ﹤0.01% 1637
2024
Q4 		$395K Buy
20,584
+8,761
+74% +$190K ﹤0.01% 1427
2024
Q3 		$269K Buy
+11,823
New +$193K ﹤0.01% 1535

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ProShare Advisors's VRDN Position: Q1 2026 in Review

ProShare Advisors reduced its Viridian Therapeutics (VRDN) stake by 19% in Q1 2026, selling an estimated $83.4K and leaving 11,794 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

ProShare Advisors first reported a position in VRDN in Q3 2024 and has held it in 7 quarters since. The position peaked at $454K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • ProShare Advisors held 11,794 shares of Viridian Therapeutics worth $231K as of Q1 2026.
  • ProShare Advisors sold 2,809 Viridian Therapeutics shares in Q1 2026, an estimated $83.4K.
  • Viridian Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1488 holding.
  • ProShare Advisors first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • ProShare Advisors's Viridian Therapeutics position peaked at $454K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.